Insider Buying: Enovis (NYSE:ENOV) Insider Acquires $25,500.00 in Stock

Enovis Corporation (NYSE:ENOV) insider Oliver Engert bought 1,000 shares of the stock in a transaction dated Friday, February 27th. The stock was purchased at an average cost of $25.50 per share, for a total transaction of $25,500.00. Following the acquisition, the insider owned 43,640 shares of the company’s stock, valued at approximately $1,112,820. This represents a 2.35% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Oliver Engert also recently made the following trade(s):

• On Wednesday, March 4th, Oliver Engert purchased 250 shares of Enovis stock. The shares were purchased at an average cost of $25.10 per share, with a total value of $6,275.00.
• On Tuesday, March 3rd, Oliver Engert acquired 1,000 shares of Enovis stock. The stock was acquired at an average cost of $24.77 per share, for a total transaction of $24,770.00.

Enovis Stock Performance

NYSE ENOV opened at $24.29 on Friday. The stock has a market capitalization of $1.39 billion, a price-to-earnings ratio of -1.17 and a beta of 1.46. The business’s 50 day moving average is $24.15 and its two-hundred day moving average is $28.08. Enovis Corporation has a 12-month low of $21.00 and a 12-month high of $40.69. The company has a current ratio of 2.02, a quick ratio of 1.04 and a debt-to-equity ratio of 0.85.

Enovis (NYSE:ENOV) last posted its quarterly earnings results on Thursday, February 26th. The company reported $0.95 earnings per share for the quarter, beating analysts’ consensus estimates of $0.81 by $0.14. Enovis had a positive return on equity of 8.74% and a negative net margin of 52.69%.The firm had revenue of $575.76 million for the quarter, compared to the consensus estimate of $584.30 million. During the same period in the previous year, the business earned $0.98 earnings per share. The company’s revenue for the quarter was up 2.6% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Research analysts expect that Enovis Corporation will post 2.79 EPS for the current year.

Analyst Upgrades and Downgrades

ENOV has been the subject of several research reports. Wells Fargo & Company lifted their price objective on Enovis from $41.00 to $42.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Canaccord Genuity Group dropped their target price on shares of Enovis from $58.00 to $50.00 and set a “buy” rating for the company in a report on Wednesday, December 17th. Zacks Research raised shares of Enovis from a “hold” rating to a “strong-buy” rating in a report on Wednesday. Evercore restated an “outperform” rating on shares of Enovis in a research report on Monday, January 12th. Finally, UBS Group reiterated a “buy” rating and set a $50.00 target price on shares of Enovis in a report on Monday, January 5th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Enovis has an average rating of “Moderate Buy” and a consensus price target of $47.43.

Institutional Investors Weigh In On Enovis

Hedge funds have recently made changes to their positions in the business. Arax Advisory Partners acquired a new position in Enovis in the fourth quarter valued at $29,000. Farther Finance Advisors LLC grew its holdings in Enovis by 42.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,224 shares of the company’s stock valued at $37,000 after buying an additional 367 shares during the period. EverSource Wealth Advisors LLC grew its holdings in Enovis by 125.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after buying an additional 707 shares during the period. Elevation Point Wealth Partners LLC acquired a new position in shares of Enovis during the 2nd quarter valued at about $46,000. Finally, SJS Investment Consulting Inc. increased its stake in shares of Enovis by 30,340.0% during the 3rd quarter. SJS Investment Consulting Inc. now owns 1,522 shares of the company’s stock valued at $46,000 after acquiring an additional 1,517 shares during the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.